Efficacy and safety of sotagliflozin in treating diabetes type 1

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

(2017) Satish K. Garg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus

(2016) Panai Song et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

(2016) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion

(2015) Brian Zambrowicz et al.   CLINICAL THERAPEUTICS

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor

(2015) Pablo Lapuerta et al.   Diabetes & Vascular Disease Research

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

(2015) Ngozi Erondu et al.   DIABETES CARE

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

(2015) Arthur T. Sands et al.   DIABETES CARE

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

(2015) Anne L. Peters et al.   DIABETES CARE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

(2015) David Powell et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

(2014) Julio Rosenstock et al.   DIABETES CARE

The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors

(2014) John P.H. Wilding   METABOLISM-CLINICAL AND EXPERIMENTAL

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes

(2013) Brian Zambrowicz et al.   CLINICAL THERAPEUTICS

Diabetic Ketoacidosis in Pregnancy

(2013) Baha M. Sibai et al.   OBSTETRICS AND GYNECOLOGY

Improved glycemic control in mice lacking Sglt1 and Sglt2

(2012) David R. Powell et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

(2011) V. Gorboulev et al.   DIABETES

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

Peri-Conceptional A1C and Risk of Serious Adverse Pregnancy Outcome in 933 Women With Type 1 Diabetes

(2009) D. M. Jensen et al.   DIABETES CARE

Novell-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes

(2009) Nicole C. Goodwin et al.   JOURNAL OF MEDICINAL CHEMISTRY